Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
Items 101–200 of 808
New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review
Nahar, L., Hagiya, H., Gotoh, K., Asaduzzaman, M., & Otsuka, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144199 · Cited by 24
“Until recently, carbapenems served as last-resort treatments for Gram-negative bacterial infections [2].”
BackgroundBarrasa, H., Rodríguez, M. Á. M., Fernández-Ciriza, L., Isla, A., Solinís, M. Á., Canut, A., & Rodríguez‐Gascón, A. (2024) · Antibiotics · doi:10.3390/antibiotics13060553 · Cited by 25
“According to IDSA guidelines [4], minocycline and tigecycline are considered for the treatment of S. maltophilia infections.”
BackgroundMethodInfluentialLoiodice, A., Bailly, S., Ruckly, S., Buetti, N., Barbier, F., Staiquly, Q., Tabah, A., Timsit, J., Tabah, A., Lipman, J., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.09.011 · Cited by 25
Sabour, S., Harrington, K. R. V., Martinson, E., Bhatnagar, A. S., Huang, J. Y., Duffy, D., Bantle, K., Lutgring, J. D., Karlsson, M., & Brown, A. C. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01220-24 · Cited by 24
Melinte, V., Radu, A. M., Văcăroiu, C. M., Mîrzan, L., Holban, T. S., Ileanu, B. V., Cismaru, I. M., & Gheorghiţă, V. (2025) · Antibiotics · doi:10.3390/antibiotics14080783 · Cited by 25
Stoian, I. A., Bălaș‐Maftei, B., Florea, C.-E., Rotaru, A., Costin, C. A., Pasare, M. A., Crișan-Dabija, R. A., & Manciuc, C. D. (2025) · Antibiotics · doi:10.3390/antibiotics15010002 · Cited by 21
“Its use remains investigational in this context and may only be considered in exceptional cases involving co-infections or as part of salvage regimens guided by susceptibility results [62].”
Management strategies for severe Pseudomonas aeruginosa infections
Rego, H. D., & Timsit, J. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000981 · Cited by 22
Wan, Y., Myall, A., Boonyasiri, A., Bolt, F., Ledda, A., Mookerjee, S., Weiße, A. Y., Getino, M., Turton, J. F., Abbas, H., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae019 · Cited by 21
Butler, D. A., Patel, N., O’Donnell, J. N., & Lodise, T. P. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae253 · Cited by 23
Microbial dynamics and pulmonary immune responses in COVID-19 secondary bacterial pneumonia
Spottiswoode, N., Tsitsiklis, A., Chu, V. T., Phan, H. V., DeVoe, C., Love, C., Ghale, R., Bloomstein, J. D., Zha, B. S., Maguire, C. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53566-x · Cited by 21
Yu, X., Yang, H., Feng, H., Hou, J., Tian, J.-Q., Niu, S., You, C., Tao, X., Zhang, S., Wang, Z., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02981-24 · Cited by 25
Verkaik, N. J., Wielders, C. C. H., den Boer, H., Langerak, D., Vogel, M., Witteveen, S., de Haan, A., Bos, J., van Westreenen, M., Notermans, D. W., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01142-24 · Cited by 20
Falcone, M., Galfo, V., & Tiseo, G. (2024) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001044 · Cited by 22
“DTR is defined as the presence of resistance to piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem, and fluoroquinolones [15].”
BackgroundEmpirical decision-making for antimicrobial therapy in critically ill patients
Ippolito, M., & Cortegiani, A. (2023) · BJA Education · doi:10.1016/j.bjae.2023.09.001 · Cited by 19
Hsu, W., Chuang, M., Tsai, W.-W., Lai, C.-C., Lai, H.-Y., & Tang, H.-J. (2024) · Infection · doi:10.1007/s15010-024-02277-y · Cited by 19
Snowdin, J. W., Mercuro, N. J., Madaio, M. P., & Rawlings, S. A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1381123 · Cited by 19
Gatti, M., Cojutti, P. G., & Pea, F. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.08.002 · Cited by 19
Thabit, A. K., Alghamdi, A. M., Miaji, M. Y., Harbi, F. A., Jawah, A. F., Alturki, F., Hosin, N., Bazuqamah, M. S., Almutairi, M. S., Alhamed, H., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1436648 · Cited by 19
Lynch, J. P. (2001) · AACN Advanced Critical Care · doi:10.1097/nci.0000000000000106 · Cited by 19
Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS Study
Bodmann, K., Hagel, S., Oliva, A., Kluge, S., Mularoni, A., Galfo, V., Falcone, M., Pletz, M. W., Lindau, S., Käding, N., et al. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01125-2 · Cited by 18
Antón-Vázquez, V., Evans, T. J., Fernando, S., Somasunderam, D., David, K., Melzer, M., Hawkins, L., Pallett, S., Morris-Jones, S. D., Arias, M., et al. (2023) · Infection Prevention in Practice · doi:10.1016/j.infpip.2023.100298 · Cited by 18
de Souza, I. L. A., Cappellano, P., Ferreira, D. B., Bergamasco, M. D., Chagas-Neto, T. C., Kerbauy, F. R., Baiocchi, O. C. G., & Pignatari, A. C. C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297161 · Cited by 18
Su, W., Song, S., Liu, J., Yu, H., Feng, B., Wu, Y., Guo, F., & Yu, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1342947 · Cited by 18
Huang, Y., Chuang, Y., Chen, P., Chou, P., & Wang, J. (2023) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae006 · Cited by 18
Diagnosing and Managing Urinary Tract Infections in Kidney Transplant Recipients
McAteer, J., & Tamma, P. D. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.03.008 · Cited by 18
Self-citationAlmangour, T. A., Alkherb, Z., Alruwaite, S., Alsahli, R., Alali, H. A., Almohaizeie, A., Almuhisen, S., Alowais, S. A., Saleh, K. B., Fetyani, L., et al. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.05.016 · Cited by 19
Fujiki, J., Yokoyama, D., Yamamoto, H., Kimura, N., Shimizu, M., Kobayashi, H., Nakamura, K., & Iwano, H. (2025) · Viruses · doi:10.3390/v17081080 · Cited by 18
“These strains are resistant to nearly all commonly used antibiotics, including carbapenems, cephalosporins, and quinolones, although they remain susceptible to colistin and novel beta-lactam–beta-lactamase inhibitor combinations such as ceftolozane-tazobactam and ceftazidime-avibactam [37,38].”
Antimicrobial prescription practices for outpatients with uncomplicated cystitis in Japan
Takahashi, M., Hagiya, H., Higashionna, T., Nakano, Y., Sato, K., Haruki, Y., Haruki, M., Honda, H., Ogawa, H., Ueda, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09946-8 · Cited by 17
Gottesdiener, L. S., & Satlin, M. J. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14169 · Cited by 20
Vega, A. D., DeRonde, K., Jiménez, A., Piazza, M., Vu, C. A., Martínez, O., Rojas, L. J., Marshall, S. H., Yasmin, M., Bonomo, R. A., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01474-23 · Cited by 17
Self-citationLan, M., Dongmei, K., Guodong, S., Haifeng, Y., Guofeng, C., Mengting, C., & Xiaoyun, F. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09335-8 · Cited by 17
“According to the Infectious Diseases Society of America (IDSA) 2023 Guidance, Carbapenem-resistant A. baumannii (CRAB) infections pose significant challenges in healthcare settings because of their uncertain antibiotic therapy and complex host status [16].”
BackgroundClinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan
Hase, R., Sakurai, A., Suzuki, M., Itoh, N., Hayakawa, K., Uemura, K., Matsumura, Y., Kato, H., Ishihara, T., van Duin, D., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae168 · Cited by 18
Karnmueng, P., Montakantikul, P., Paiboonvong, T., Plongla, R., Chatsuwan, T., & Chumnumwat, S. (2024) · Clinical and Translational Science · doi:10.1111/cts.13855 · Cited by 17
“6,7 For NDM-producing infections, the preferred options are ceftazidime–avibactam in combination with aztreonam or cefiderocol, while ceftazidime–avibactam or cefiderocol is suggested for OXA-48.”
BackgroundZhang, F., Li, Z., Liu, X., Li, Z., Lei, Z., Zhao, J., Zhang, Y., Wu, Y., Yang, X., & Lu, B. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107327 · Cited by 17
Guo, W., Lin, Q., Li, J., Feng, X., Zhen, S., Mi, Y., Zheng, Y., Zhang, F., Xiao, Z., Jiang, E., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01011-24 · Cited by 17
Černiauskienė, K., & Vitkauskienė, A. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10010015 · Cited by 17
“Thus, currently, there is no consensus on the strategies for the optimal treatment of carbapenem-resistant A. baumannii infections, and different guidelines advocate different recommendations and advice [10,11].”
Hareza, D. A., Bergman, Y., Jacobs, E. B., Lu, J., Hanson, N. D., Conzemius, R., Cosgrove, S. E., Harris, A. D., Simner, P. J., & Tamma, P. D. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01258-24 · Cited by 17
Self-citationMuhamad, A. N., Teh, C. S. J., Yusof, M. R. D., Adnan, Y. K., Abbas, A. A., Khong, T. L., Narayanan, V., Tang, S. N., Karunakaran, R., Manan, N. A., et al. (2025) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-025-01537-2 · Cited by 17
Liao, J. X., Appaneal, H. J., Menon, A., Lopes, V., LaPlante, K. L., & Caffrey, A. R. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00827-9 · Cited by 16
Raúl, N.-S. J., López-Jácome, L. E., Franco‐Cendejas, R., Colín‐Castro, C. A., Hernández-Durán, M., Rivera-Garay, L. R., Zamarripa-Martinez, K. S., & Mosqueda-Gómez, J. L. (2023) · Antibiotics · doi:10.3390/antibiotics12081295 · Cited by 16
“For MBL-producing strains, there are more limited options, especially the combination of ceftazidime/avibactam with aztreonam or cefiderocol as monotherapy, whereas tigecycline, eravacycline, and polymyxins remain as alternative but more toxic options, regardless of the presence of carbapenemases [18,23].”
BackgroundInfluentialStenotrophomonas maltophilia: An Urgent Threat with Increasing Antibiotic Resistance
Liu, J., Xiang, Y., & Zhang, Y. (2023) · Current Microbiology · doi:10.1007/s00284-023-03524-5 · Cited by 20
Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections
Pipitone, G., Bella, S. D., Maraolo, A. E., Granata, G., Gatti, M., Principe, L., Russo, A., Gizzi, A., Pallone, R., Cascio, A., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12121653 · Cited by 16
“Usually, combination therapy is not recommended, although it is considered in some instances [1].”
BackgroundVolpicelli, L., Cairoli, S., Ismail, D. A., Baisi, F., Sacco, F., Goffredo, B. M., Venditti, M., & Oliva, A. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.03.003 · Cited by 16
Marais, G. J. K., Moodley, C., Claassen-Weitz, S., Patel, F., Prentice, E., Tootla, H. D., Nyakutira, N., Lennard, K. S., Reddy, K., Bamford, C., et al. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae050 · Cited by 18
New Agents Are Coming, and So Is the Resistance
Keck, J. M., Viteri, A., Schultz, J., Fong, R., Whitman, C., Poush, M., & Martin, M. (2024) · Antibiotics · doi:10.3390/antibiotics13070648 · Cited by 17
“In 2023, the ISDA published updated guidance documents for the treatment of antimicrobial-resistant Gram-negative infections [23].”
BackgroundResultInfluentialGuidelines for Antibiotics Prescription in Critically Ill Patients
Chaudhry, D., Desai, M., Gupta, M., Mohan, A., Mehta, Y. B., Sengar, M., Govil, D., Hegde, A. V., Rungta, N., Mittal, S., et al. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24677 · Cited by 20
Bakthavatchalam, Y. D., Manoharan, Y., Shankar, A., Gunasekaran, K., Walia, K., & Veeraraghavan, B. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04932-6 · Cited by 16
Li, M.-T., Wu, Q.-Q., Li, J.-B., & Chen, J. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107033 · Cited by 16
Hevia, E. C., Wooten, L., & Carr, A. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231201850 · Cited by 15
Tsai, M., Chen, C., Chang, H.-J., Chuang, T.-C., & Chiu, C. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.03.014 · Cited by 15
Novel Antibiotics for Gram-Negative Nosocomial Pneumonia
Almyroudi, M. P., Chang, A., Andrianopoulos, I., Παπαθανάκος, Γ., Mehta, R., Paramythiotou, E., & Koulenti, D. (2024) · Antibiotics · doi:10.3390/antibiotics13070629 · Cited by 15
“Furthermore, mutations in PDCs are responsible for the emergence of resistant strains of P. aeruginosa [48].”
BackgroundInfluentialAnand, A., Verma, A., Kaur, S., Kathayat, P., Manoj, R. M., Aakanksha, A., Turzin, J. K., Satapathy, P., Khatib, M. N., Gaidhane, S., et al. (2024) · Health Science Reports · doi:10.1002/hsr2.70066 · Cited by 15
“23 However, cefiderocol is usually reserved for refractory CRAB infections.”
BackgroundInfluentialKhan, R., Wali, S., Khan, S., Munir, S., PARI, B., Yousuf, A., & Almutawif, Y. A. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1473055 · Cited by 15
Lemon, J. K., Jankowsi-Romano, C., Duong, S., Juretschko, S., & Streva, V. A. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.00649-24 · Cited by 15
Kabbara, W. K., Sadek, E., & Mansour, H. (2025) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/cjid/2001136 · Cited by 15
Vu, C., Venugopalan, V., Santevecchi, B. A., Voils, S. A., Ramphal, R., Cherabuddi, K., & DeSear, K. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.21 · Cited by 15
Nulsopapon, P., Pongchaidecha, M., Nasomsong, W., Polwichai, P., Suphankong, S., Sirichote, P., Chaisomboonpan, S., & Santimaleeworagun, W. (2022) · Antibiotics · doi:10.3390/antibiotics11030355 · Cited by 14
Mileto, I., Petazzoni, G., Corbella, M., Gaiarsa, S., Merla, C., Kuka, A., Ramus, M., Terulla, C., Brandolini, M., Piralla, A., et al. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.42.2300522 · Cited by 14
“Cefiderocol or ceftazi-dime-avibactam in combination with aztreonam are the preferred antibiotic options for NDM-producing Enterobacterales [1].”
BackgroundZalacaín, M., Achard, P., Llanos, A., Morrissey, I., Hawser, S., Holden, K. A., Toomey, E., Davies, D. T., Leiris, S. J., Sable, C. A., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-23 · Cited by 14
Shmoury, A. H., Hanna, W., Zakhour, J., Zahreddine, N. K., & Kanj, S. S. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.03.022 · Cited by 15
Babiker, A., Lohsen, S., Riel, J. A. V., Hjort, K., Weiss, D. S., Andersson, D. I., & Satola, S. W. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae057 · Cited by 14
Sapula, S. A., Hart, B. J., Siderius, N. L., Amsalu, A., Blaikie, J. M., & Venter, H. (2024) · MicrobiologyOpen · doi:10.1002/mbo3.1409 · Cited by 15
Maccari, L., Ceriana, P., Granchetti, H. N., Pezzaniti, A., Lucero, C., Rapoport, M., Menocal, A., Corso, A. C., & Pasterán, F. G. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01255-23 · Cited by 14
Wilhelm, C. M., Antochevis, L. C., Magagnin, C. M., Arns, B., Vieceli, T., Pereira, D. C., Lutz, L., de Souza, Â. C., dos Santos, J. N., Guerra, R. R., et al. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.06.007 · Cited by 14
Casale, R., Boattini, M., Comini, S., Bastos, P. A. D., Corcione, S., Rosa, F. G. D., Bianco, G., & Costa, C. S. (2024) · Infection · doi:10.1007/s15010-024-02342-6 · Cited by 14
Fu, Y., Asempa, T. E., & Kuti, J. L. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2440018 · Cited by 14
“Before the approval of sulbactam-durlobactam, high-dose ampicillin-sulbactam, carbapenems, polymyxin B, high-dose tetracyclines (minocycline or tigecycline), and cefiderocol were the treatment options for Acinetobacter -related infections [65].”
Jian, Z., Liu, Y., Wang, Z., Liu, P., Wang, J., Yan, Q., & Liu, W. (2025) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-024-00769-1 · Cited by 14
“These guidelines advocate for either a combination therapy utilizing ceftazidime-avi-bactam and aztreonam or monotherapy with cefiderocol [30, 31].”
Emerging carbapenem-resistant Klebsiella pneumoniae in a tertiary care hospital in Lima, Peru
Krapp, F., Cuicapuza, D., Guillermo Salvatierra, R., Buteau, J., Amaro, C., Astocondor, L., Hinostroza, N., Jacobs, J. A., García, C., & Tsukayama, P. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01825-24 · Cited by 14
Balbuena, J. P., Córdova, E., Mykietiuk, A., Farina, J., Gañete, M., Scapellato, P. G., Lespada, M. I., Nannini, E. C., Contreras, R. D. P., Cunto, E., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf259 · Cited by 15
O’Donnell, J. P., Tanudra, A., Chen, A., Newman, J. V., McLeod, S. M., & Tommasi, R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00800-23 · Cited by 14
Horcajada, J. P., Gales, A. C., Isler, B., Kaye, K. S., Kwa, A. L., Landersdorfer, C. B., Montero, M., Oliver, A., Pogue, J. M., Shields, R. K., et al. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00233-24 · Cited by 13
Davis, K. P., Morales, Y., Ende, R. J., Peters, R., McCabe, A. L., Mecsas, J. C., & Aldridge, B. B. (2024) · mBio · doi:10.1128/mbio.00159-24 · Cited by 14
Grome, H. N., Grass, J. E., Duffy, N., Bulens, S. N., Ansari, U. A., Campbell, D., Lutgring, J. D., Gargis, A. S., Masters, T. L., Kent, A. G., et al. (2024) · Emerging infectious diseases · doi:10.3201/eid3006.231734 · Cited by 15
“Few antimicrobial drugs can treat CRE and ESBL-E infections ( 10 ), and limited pediatric-specific clinical trials of antimi - crobial drugs contribute to a scarcity of knowledge with regard to children compared with adults ( 11 ).”
Chou, S.-H., Chuang, C., Juan, C.-H., Ho, Y.-C., Liu, S.-Y., Chen, L., & Lin, Y.-T. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107244 · Cited by 13
Wei, M., Chen, X., Liu, J., Li, T., Wang, P., Wang, S., Wang, J., & Gu, L. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s475630 · Cited by 15
“28,29 mCIM/eCIM and inhibitor-based CDT for the detection of carbapenemase in CP-CRE isolates were recommended by CLSI 19 and EUCAST, 30 respectively. mCIMandeCIM can distinguish between serine carbapenemase (KPC and OXA-48-like) and MBL (NDM, IMP, and VIM), but it cannot further classify them.…”
MethodFirst report of a blaNDM-producing extensively drug resistant Klebsiella pneumoniae ST437 in Italy
Ranieri, S. C., Fabbrizi, V., Amario, A. M. D., Frascella, M. G., Biase, V. D., Francesco, C. D., Sante, S. D., Berardis, L. D., Martinis, M. D., Partenza, M., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1426817 · Cited by 14
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
Kirkegaard-Biosca, C., del Barrio-Tofiño, E., Villamarín, M., Larrosa, N., Campany, D., González‐López, J. J., Ferrer, R., Viñado, B., Moral, L. D., Sellarès-Nadal, J., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13090874 · Cited by 13
“The recommended treatments for MBL-producing Enterobacterales include CZA+ATM and cefiderocol [2].”
BackgroundInfluentialUngthammakhun, C., Vasikasin, V., Simsiriporn, W., Juntanawiwat, P., & Changpradub, D. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107267 · Cited by 13
Onorato, L., de Luca, I., Salvati, A., Monari, C., & Coppola, N. (2024) · Infection · doi:10.1007/s15010-024-02447-y · Cited by 13
Graves, E. T., Wardlow, L. C., Ogake, S. B., Bazan, J. A., Coe, K. E., Kuntz, K., & Elefritz, J. L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf024 · Cited by 13
Saggers, R. T., Mothibi, L. M., Irwin, A., & Naidoo, K. D. (2023) · Current Infectious Disease Reports · doi:10.1007/s11908-023-00817-5 · Cited by 16
Leus, I. V., Roberts, S. R., Trinh, A., Yu, E. W., & Zgurskaya, H. I. (2023) · Journal of Bacteriology · doi:10.1128/jb.00217-23 · Cited by 13
Herrera, F., Torres, D., Laborde, A., Jordán, R., Mañez, N., Berruezo, L. A., Lambert, S., Suchowiercha, N., Costantini, P., Nenna, A., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12010195 · Cited by 13
“Despite the lack of an empirical approach, they suggest that it should be based on variables such as the pathogens most likely involved, severity and source of infection, and severe immune compromise, among others [14].”
BackgroundApproaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory
Russo, C., & Humphries, R. M. (2023) · Antibiotics · doi:10.3390/antibiotics12121700 · Cited by 12
“…laboratories should consider confirming any CZA resistant results in Enterobacterales that are negative for an MBL. Carbapenem and CZA resistance is often indicative of the presence of an MBL, and this supposition should be confirmed, for treatment [14] and epidemiological/infection control purposes.”
BackgroundInfluentialCurrent treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii
Franzone, J., Mackow, N., & van Duin, D. (2024) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001001 · Cited by 12
“The IDSA recommends only using cefiderocol to treat CRAB infections refractory to other agents and only in combination with other CRAB-directed antibiotics [21 & ].”
BackgroundMethodInfluentialRueda, F. R., Méndez, R., Suárez-de-la-Rica, A., González, R., & Maseda, E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010106 · Cited by 17
“These guidelines are very balanced and indicative and have a very similar background, often based on up-to-date expert opinion, due to the rapid emergence of new drugs and published evidence, or using a GRADE methodology [64,75,76].”
BackgroundMethodTebipenem and Sulopenem: Dynamic Duo or Double Trouble?
Mangum, B. R., Pogue, J. M., & Barber, K. E. (2024) · Current Infectious Disease Reports · doi:10.1007/s11908-024-00831-1 · Cited by 12
Mauritz, M. D., Claus, B., Förster, J., Petzold, M., Schneitler, S., Halfmann, A., Hauswaldt, S., Nurjadi, D., & Toepfner, N. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.03.010 · Cited by 12
González, K. S. G., Vásquez‐Mendoza, A. F., & Rodríguez, C. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116428 · Cited by 12
The challenges of difficult-to-treat Acinetobacter infections
Richards, G. A., Perovic, O., & Brink, A. J. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00093-24 · Cited by 12
Mengistu, G., Roberts, J. A., Aslan, A. T., Mohammed, S. A., & Sime, F. B. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae451 · Cited by 12
Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023
Hamilton, F., Darley, E. S. R., Arnold, K., & MacGowan, A. P. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae440 · Cited by 12
Najafabadi, M. K., & Soltani, R. (2024) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_50_24 · Cited by 12
“[59,60] However, three-drug combinations with other potentially active antibiotics, such as ampicillin/sulbactam or tigecycline, plus colistin and meropenem, could be considered a treatment option for CRAB infections.”
Baghdadi, J. D., Goodman, K. E., Magder, L. S., Claeys, K. C., Sutherland, M. E., & Harris, A. D. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf039 · Cited by 15
Montero, M., Domene-Ochoa, S., Prim, N., Ferola, E., López-Causapé, C., Gomis-Font, M., Morisaki, M. A., Echeverría-Esnal, D., Sorlí, L., Luque, S., et al. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05061-4 · Cited by 12
Kim, T., Jeon, E. H., Hong, Y.-K., Jung, J., Kim, M. J., Sung, H., Kim, M., Kim, S., Choi, S., Lee, S., et al. (2025) · Infection and Chemotherapy · doi:10.3947/ic.2024.0110 · Cited by 12
“Minocycline, a semisynthetic derivative of tetracycline, has been suggested as a potential therapeutic option for CRAB infections [6].”
Berteau, F., Kouatchet, A., Gall, Y. L., Pouplet, C., Delbove, A., Darreau, C., Lemarie, J., Jarousseau, F., Reizine, F., Giacardi, C., et al. (2025) · Annals of Intensive Care · doi:10.1186/s13613-025-01468-6 · Cited by 12
Itani, R., Khojah, H. M. J., Mukattash, T. L., Shuhaiber, P., Raychouni, H., Dib, C., Hassan, M., & El-Lakany, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321935 · Cited by 13
Synergistic Effects of Gentamicin, Cefepime, and Ciprofloxacin on Biofilm of Pseudomonas aeruginosa
Usman, M., Marcus, A., Aslam, B., Zaid, M., Khattak, M., Bashir, S., Masood, S., Masood, S., Usman, M., & Dasti, J. I. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s426111 · Cited by 12
Zhang, X.-P., Deng, X.-C., Gao, Z.-H., & Cui, G. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136950 · Cited by 12
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.